About Aosaikang The company has 14 products approv for marketing, including sintilimab injection (Daboshu®,
bevacizumab injection ( Dayoutong® , adalimumab injection (Sulixin® , rituximab injection (
Dabohua® , pemigatinib tablets (Dabotan® , orebactinib tablets (Nailike® , ramucirumab injection
(Xiranze®, sepretib capsules (Ruitu® , ikiorencel phone number list injection ( Fucosu® , tolcizumab injection (Simbil® ,
floxacin tablets (Dabot® , pitubutinib tablets (Jepali® , taretinib adipate capsules (Dabolu® and
rietinib tablets (Aoyixin® . At present, there are 3 varieties under review by NMPA, 3 new drug
molecules have enter Phase III or key clinical studies, and another 17 new drug varieties have enter clinical research.
The company has enter into more than 30 strategic collaborations with international partners including Eli Lilly, Roche, Sanofi, Adimab, Incyte and MD Anderson Cancer Center.
While continuously developing innovative drugs and pursuing its own development
Innovent Biologics adheres to the development philosophy of putting people at the center of economic
construction. Over the years, we have always been scientific and kind, adher to the “patientcenter”
principle, car about patients and their families, and actively fulfill our social responsibilities. The
company has initiat and participat in a number of public welfare drug assistance projects, enabling
more and more patients to benefit from the progress in the context of the fourth industrial revolution of life sciences and to buy and afford highquality
biological drugs. To date, Innovent Biologics’ patient assistance program has benefit more than
170,000 ordinary patients, with the total value of drug donations reaching RMB 3.4 billion. Innovent
Biologics hopes to work with everyone to improve the development level of China’s biopharmaceutical
industry to meet people’s access to micines and their pursuit of a better life and health.
For more information, please visit the company’s website: .innoventbio or the company’s LinkIn account: .linkincompanyinnoventbiologics .
Statement: 1. Innovent Biologics does not recommend the use of unapprov drugsindications
2. Ramucirumab injection (Ciranze® , sepretinib capsules (Reitu® and pitutinib tablets (Jepagliflozin® were develop by Eli Lilly and trust review Company
Found in 2003, Aosaikang Pharmaceutical is an innovation and R&Ddriven pharmaceutical
manufacturer. The company independently develop China’s first domestically produc proton pump
inhibitor (PPI injection. After more than 20 years of development, the company’s drug treatment
areas have cover four major areas: digestion, antitumor, antiinfection and chronic diseases. It has a high brand influence in the Chinese pharmaceutical market segment About Aosaikang.